(2S)-3-[[2-[[3-[[2-(adamantane-1-carbonylamino)acetyl]amino]-5-guanidinobenzoyl]amino]acetyl]amino]-2-[[(2S)-1-(benzenesulfonyl)pyrrolidine-2-carbonyl]amino]propanoic acid

ID: ALA4756339

Chembl Id: CHEMBL4756339

PubChem CID: 162655545

Max Phase: Preclinical

Molecular Formula: C37H47N9O9S

Molecular Weight: 793.90

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  N=C(N)Nc1cc(NC(=O)CNC(=O)C23CC4CC(CC(C4)C2)C3)cc(C(=O)NCC(=O)NC[C@H](NC(=O)[C@@H]2CCCN2S(=O)(=O)c2ccccc2)C(=O)O)c1

Standard InChI:  InChI=1S/C37H47N9O9S/c38-36(39)44-26-13-24(12-25(14-26)43-31(48)20-42-35(53)37-15-21-9-22(16-37)11-23(10-21)17-37)32(49)41-19-30(47)40-18-28(34(51)52)45-33(50)29-7-4-8-46(29)56(54,55)27-5-2-1-3-6-27/h1-3,5-6,12-14,21-23,28-29H,4,7-11,15-20H2,(H,40,47)(H,41,49)(H,42,53)(H,43,48)(H,45,50)(H,51,52)(H4,38,39,44)/t21?,22?,23?,28-,29-,37?/m0/s1

Standard InChI Key:  SQTQEWRATPPDHW-QRFGUKROSA-N

Alternative Forms

  1. Parent:

    ALA4756339

    ---

Associated Targets(Human)

ITGB1 Tclin Integrin alpha-5/beta-1 (686 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ITGB1 Tclin Integrin alpha-V/beta-1 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ITGB3 Tclin Integrin alpha-V/beta-3 (2708 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ITGAV Tchem Integrin alpha-V/beta-5 (589 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ITGAV Tchem Integrin alpha-V/beta-6 (509 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ITGAV Tchem Integrin alpha-V/beta-8 (181 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ITGB1 Tclin Integrin alpha-4/beta-1 (2269 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 793.90Molecular Weight (Monoisotopic): 793.3217AlogP: 0.53#Rotatable Bonds: 15
Polar Surface Area: 282.08Molecular Species: ZWITTERIONHBA: 9HBD: 9
#RO5 Violations: 2HBA (Lipinski): 18HBD (Lipinski): 10#RO5 Violations (Lipinski): 3
CX Acidic pKa: 3.03CX Basic pKa: 8.99CX LogP: -1.94CX LogD: -1.95
Aromatic Rings: 2Heavy Atoms: 56QED Weighted: 0.09Np Likeness Score: -1.19

References

1. Sundaram A,Chen C,Isik Reed N,Liu S,Ki Yeon S,McIntosh J,Tang YZ,Yang H,Adler M,Beresis R,Seiple IB,Sheppard D,DeGrado WF,Jo H.  (2020)  Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.,  30  (22): [PMID:33007395] [10.1016/j.bmcl.2020.127578]

Source